Product
VIR-3434
Aliases
Tobevibart
6 clinical trials
6 indications
Indication
Hepatitis BIndication
ChronicIndication
Chronic Hepatitis BIndication
Liver ImpairmentIndication
CirrhosisIndication
Hepatitis DClinical trial
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants With Chronic Hepatitis B Infection (PREVAIL)Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434Status: Completed, Estimated PCD: 2022-10-24
Clinical trial
Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B InfectionStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2026-09-25
Clinical trial
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)Status: Recruiting, Estimated PCD: 2029-08-01